Syntara Limited (SNT.AX)
- Previous Close
0.0160 - Open
0.0160 - Bid 0.0160 x --
- Ask 0.0170 x --
- Day's Range
0.0160 - 0.0170 - 52 Week Range
0.0140 - 0.0300 - Volume
4,541 - Avg. Volume
1,424,423 - Market Cap (intraday)
20.297M - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Feb 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.10
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
www.syntaratx.com.au27
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: SNT.AX
Performance Overview: SNT.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNT.AX
Valuation Measures
Market Cap
20.30M
Enterprise Value
15.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.24
Enterprise Value/Revenue
2.61
Enterprise Value/EBITDA
-1.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.84%
Return on Assets (ttm)
-34.55%
Return on Equity (ttm)
-97.62%
Revenue (ttm)
19.18M
Net Income Avi to Common (ttm)
-10.69M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
5.69M
Total Debt/Equity (mrq)
7.23%
Levered Free Cash Flow (ttm)
-1.58M
Research Analysis: SNT.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: SNT.AX
SNT.AX does not have Company Insights